Thank you, James (ph.). Hello, everyone. Thank you for taking the time to join us this afternoon. Before we begin, I'd like to express our deep appreciation for all of our shareholders including both institutional and especially our retail investors, for all of the support that you've given us over the past year. Our goals are aligned and we look to create significant shareholder value for everyone in the future. Let me begin by expressing how pleased we are with the financial results during the second quarter. We generated net revenue of 9.1 million, including 8.7 million from XpresCheck, and narrowed our Adjusted EBITDA loss to 2.3 million down from 3.4 million in the prior-year second quarter. The improvement of $1.1 million is indicative of the profitability of XpresCheck compared to our legacy XpresSpa segment. We also narrowed our net loss to 4.5 million from 58.5 million and retained a strong liquidity position with an unrestricted cash balance of $102.5 million. I want to be clear on a new view that we see as we look to the future. At one point, we believe the future of the airport Spa business was highly uncertain considering the nature of the high personal touch business. We believe that XpresCheck would be a short-term bridge to the future. We also believe that Treat would be the sole destination as it combines the most relevant parts of XpresSpa and XpresCheck and expands the health and wellness services for travelers while adding a significant digital engine so revenue is no longer limited to the airports where we operate units. Now, we see a much bigger opportunity based on our experience during this pandemic. The data that we have collected and analyzed, and customer views. We now see three sustainable business models for the future. We are transitioning from a Company operating a singular concept, to a family of a relative -- of relevant travel, health, and wellness brands with a lot of runways ahead of us. We see multiple brands that we believe have the potential to operate efficiently, simultaneously, and profitably, over the long run. I would now like to share some thoughts on where we currently stand with respect to our airport-based XpresCheck and XpresSpa businesses. Then I will take you on our new brand, Treat, and how we intend to capitalize on what we believe is a large opportunity in the travel health enrollment space. Beginning with the XpresCheck brand in April, we opened 2 XpresCheck locations, the first in Seattle-Tacoma International Airport and the second in San Francisco International Airport. Today, we Operate 13 XpresCheck Wellness Centers, 7 days a week across 11 airports. In fact, agreement extensions have been agreed to at the first two airports that we've opened XpresCheck in last year, John F. Kennedy International Airport and Newark Liberty International Airport. As you may recall, at the onset of the pandemic in March 2020, we moved extremely quickly on our vision for XpresCheck due to the vast opportunity we saw for COVID-19 testing at major U.S. airports. We piloted, we learned, and we launched. Since then, XpresCheck has surpassed all of the expectations we have for the brand and we're very pleased with the results even as vaccination rates rise. For example, patient testing was at an all-time high during the Second Quarter, increasing 146% sequentially when compared to the First Quarter this year. We believe even with an increase in vaccination levels, on-site COVID-19 testing will still be an important and necessary service where airline employees and passengers alike for the foreseeable future due to several factors, including COVID-19 variant proliferation, ongoing international requirements, and breakthrough vaccination infection rates. International travel represents a significant portion of our patient base as many countries outside the U.S. continue to require a COVID-19 PCR test prior to arrival. We do not see many countries changing this policy any time in the near future, and exposing their citizens to additional risk. There are simply not enough vaccines to meet the global demand, and the wealthy countries are monopolizing most of the supply. And further, now considering adding booster vaccinations. According to a Wall Street Journal article this past Friday, at the current rate, much of the world would remain unvaccinated, and global stability out of reach until maybe 2023. XpresCheck also continues to benefit from the range of rapid COVID tests that we're -- that we offer which is substantially higher and more expensive in price point with $200 to $250 versus $75 for the standard PCR test or the blood antibody test that we initially launched with. Almost all tests are now rapid, which has helped significantly improved gross margins and minimize our cash burn. As a reminder, it was only March of this year when we transitioned to a fee-for-service model for all testing which has helped significantly improved our cash flow. Now, all patients pay upfront at the time of service, and then they are able to submit their testing fees for insurance reimbursement on their own. The testing business has ramped up much faster than we expected. Our medical practices saw revenues over 17 million in Q2, almost triple what was seen in the first quarter. We are confident that this will continue over the foreseeable future. Not only has testing ramped faster in any other part of our past file business, but the four-wall Performa margins continue to grow faster than any initiative that we have implemented in our spas, and the yield and return on our investment under -- in under 3 months. At the end of 2020, we promoted Scott Milford to Chief Operating Officer. Scott has quickly increased labor productivity and worked diligently to expand our operational hours to meet those -- the needs of those requiring COVID testing while still only operating when the terminals are the busiest to ensure profitability. Scott and our new CFO, James Berry, have brought a sharp focus on financial discipline, cash generation, and the execution of our operational strategies while still creating an employer of choice, People Culture. In late July, we announced a partnership with the Go Give One campaign. The Go Give One campaign was created by the World Health Organization Foundation and is dedicated to funding COVID-19 vaccines worldwide in the fight to reduce the growing vaccine equity gap. As a kickoff to the campaign, XpresSpa is matching public donations up to an aggregate of $100,000. We are honored to support this incredible campaign in the fight against COVID-19 for those in lower-income countries lacking access to critical vaccinations. Our investment in the health and wellness of our customers has opened up the door for this incredible partnership, which we hope to continue to grow in the future. Additionally, last week, we received approval for a $2 million contract with the Centers for Disease Control and Prevention, the CDC for bio surveillance tracking at 3 airports: JFK International Airport, Newark Liberty International Airport, and San Francisco International Airport. Many of you will remember that I have spoken about our government affairs efforts with the federal government over the past year. This is one of the outputs from those many conversations. This is an 8-week program with a 6-month contract with the CDC that is aimed at identifying existing and new COVID-19 variants, including the highly contagious Delta variant and other new variants surfacing that could start surfacing in the U.S. Let me be clear, this 6-month contract with the 6-month extension in place allows the CDC at their discretion to Direct XpresCheck to set up a national bio surveillance program, with installments of incremental funding in any or all airports, regardless of whether there's an XpresCheck, fully operating, in place. The CDC has the ability to dictate how real estate is used in airports for national safety concerns. Whereas the current XpresCheck model requires the airport to grant access to the real estate on an airport by airport basis. The first $2 million commitment is only for this 8-week pilot across 3 airports, targeting 7 daily flights. While we're starting with the incoming flights from India, we're testing and developing a protocol for future interventions that can be directed to many flights arriving from various countries of concern. The program is being developed -- the program being developed could easily be implemented for any incoming port beyond airports upon the CDC's direction. And because this at-the-gate program primarily includes the collection of self-administered passenger swaps that XpresCheck sends out to select external labs for the testing similar to what is used by children in some elementary school COVID testing programs. There is not a limit to capacity that we might typically have in an XpresCheck facility with a specific number of testing rooms. As this program expands, we see this as a potentially significant business line extension for XpresCheck, and with the foundation of the government contract in place. Again, we will pilot, we will look to learn, we plan to launch. Our collaborations with government agencies, like the CDC, demonstrates the confidence these agencies have in the XpresCheck brand. XpresCheck aims to further its relationship with the CDC and extend the program into all major U.S. international airports in the near future. Based on what we have learned, and are seen today, COVID-19 testing. COVID-19 testing, let alone future infectious disease testing, is here to stay for the foreseeable future for people traveling internationally in and out of the U.S. XpresCheck also continues to work with several airlines providing COVID-19 testing for passengers to select a location. In April, we signed an agreement with Delta Airlines to administer the new rapid antigen test to customers traveling from Jonathan Kennedy International Airport, the Milan Malpensa in Rome, Moschino International airports. In early August, we launched a pilot program with El Al, Israeli Airlines, the national airline of Israel. The State of Israel requires a negative COVID-19 PCR test within 72 hours of the traveler -- travel from passengers and flight crew departing the U.S. and then another COVID-19 PCR test once arriving and then Gurion International Airport in Tel Aviv. If this pilot is successful and XpresCheck may provide free travel, rapid COVID-19 PCR testing on-site at JFK and other U.S. airports for all El Al passengers and crew on multiple daily flights in place of the second PCR administered in Israel. The protocol will get U.S.-originating El Al passengers out of the airport significantly faster after a 10+ hour flight, than sitting in line with all the other arriving passengers from other -- from every country and other airline in the queue for an onsite COVID-19 test before being released from the airport. Again, we piloted, we learned, and we're looking to launch. Now, turning to the airport business. On July 1st, we reopened 4 historically top-performing XpresSpa locations. These locations include Hartsfield-Jackson, Atlanta International, in Concourse A, Dallas Forth worth International Airport, in Concourse A, Charlotte Douglas International Airport, Concourse D, and Las Vegas McCarran International Airport, concourse D. In order to maximize profitability across these spas, we negotiated the right to operate these 4 spas during the busiest hours, and only start with our highest performing services, which are massages, manicures, and pedicures. As a reminder, we've already opened our 2 XpresSpa locations at Dubai International Airport in the UAE. And a single franchised XpresSpa location in Austen Bergstrom International Airport. We also opened a new XpresSpa expanded concept on July -- on June 17th, in Dubai International Airport. This is an international wellness prototype focused on testing new wellness treatments in technology, expanding our core XpresSpa offerings, to hopefully export the winners into existing domestic and international U.S.-- International XpresSpa businesses. To date, this brings us up to 8 XpresSpa locations currently reopened and operating. As we analyze the first 30 days of performance of the 4 high-volume U.S. locations that we opened on July 1st. Their sales are lower than previous 2019 run rates, despite the increase in airport traffic and rising vaccination levels. The good news is, that even with the lower revenue baseline, we believe we can generate the same or better gross profit margins with -- while the legacy Xpress -- while the legacy spa business on its own may not have been highly profitable in the past, today it has the benefit of cost-cutting measures we implemented in 2019, as well as sharing the corporate overhead across 2 other operating brands, leveraging the same corporate support structure. Our operations team is currently reviewing our pricing, service model, and labor model, to find further upside beyond the efficiencies of operating reduced hours during the airport's busiest times, as vaccination rates increase and airport traffic continues to return, especially with anxious flyers and business travelers. We've been a significant service segment in the past. We see enthusiasm for travel spa services and -- at airports returning. We now have plans to open the next wave of 8 to 10 high-performing XpresSpa s by early fall to continue the profitable restoration of the pre -COVID business -- of the pre -COVID business model of 40 to 50 million in annual revenue as the economy reopens. We piloted re-openings. We are learning. We are re-launching. We will continue to reevaluate each airport on a month-by-month basis, as well as review continued learnings as our Portfolio continues to be reactivated. Now let's discuss our new brand Treat. Comprehensive travel, health, and wellness, the concept that is positioned for the post-pandemic world. While this multi-channeled business is coming to market in record time in 2021, to take advantage of this singular moment in history, the return to travel, it has a runway to be a larger business than XpresSpa or XpresCheck with better revenue in gross margins over time. Treat started as a division of our collective new executive team, after many planning sessions in late 2019, and early 2020. The brand and concept have been refined by one of our new executives, Kelsey Hanson (ph.), SVP of Marketing and Communications, who has wrapped these services with a beautiful lifestyle brand, with timely digital content in a modern retail store design that connects with today's reemerging traveler. Through this leadership team's strategic thinking, we found a way to leverage XpresSpa historic travel wellness experience, and XpresCheck healthcare expertise to provide travelers access to integrated healthcare through technology and on-site personalized services. We have a classic need and want to converge. People want to get back to traveling but need to do it safely and responsibly. We are not building an average brand, for average people, at above-average prices. We are passionately working towards creating a concept worth creating, with a story worth telling, and a contribution worth talking about. Treat is positioned to be a leader in what we view as an emerging new category of health-focused travel and personal loan and services. Treat will act as a wellness concierge, providing original content to help you plan to travel, as well as medical care and wellness services to consumers, as they return to travel. Through Treat's mobile app, travelers will be able to access 24/7 on-demand virtual healthcare. A travel health wallet with your medical records, and real-time global COVID-19 travel requirements all in one place, as well as book appointments in our on-site wellness centers as they open. Our goal is to be a travel champion, making it easier for you to be well as you return to traveling the world. To ensure a seamless launch of this new brand, we're rolling Treat out in 3 distinct phases. If you recall, on our Q1 earnings call in May, we announced Phase One of the new brand, our website, www.treatcare.com, and the brand campaign would launch in June. Thanks to the hard work of our new Chief Technology Officer, David Cole (ph.). We met this target and officially launched our website on 01/06. The Treat website features original content, access to resources about COVID-19 requirements for travelers, and curated e-commerce with emerging products targeting the savvy traveler living a wellness lifestyle. The initial website launch is gaining traction daily. We have over 1,000 -- 100,000 unique visitors. The website also allows consumers to opt-in to biweekly newsletter. The treatment, which has started with over a thousand readers in an average 30 to 35% Saturday morning open rate. If you've not signed up for the treatment on treat care.com, I think you'll enjoy it. As seen in the press release issued this morning, phase 2 of Treat's mobile app launched today. Our internal goal was to have this mobile app up and running by the end of summer as communicated on our last earnings call. I'm happy to report that through the team's smart work led by David, we started on the track and launched ahead of schedule. The mobile app is available today at no charge for Apple and Android devices and provides access to on-demand virtual care, including check care, video care, and a travel alignment with access to a person's medical records and test results. Memberships are available, which include a mobile app subscription with access to Unlimited 24/7 on-demand medical cam virtually. Also included in the membership is 1 free PCR COVID-19 test, 1 free flu vaccine shot per year, and discounts on prescriptions, which will be added in a few weeks. Over time, there will be additional capabilities added to the app, such as in-person scheduling once our airport wellness centers locations begin to open, plus other exclusive offers and discounts. Memberships start at $200 for 3 months or can be $720 for 12 months. Now moving onto Phase 3, which includes the launch of Treat in the Airport wellness centers, which will both leverage some of our existing airport real estates as well as take shape and new spaces. We're starting construction this week and plan to open the first pilot location, JFK -- at JFK terminal 4 in mid Q4 in a converted XpresSpa location and a second pilot Treat location in Phoenix Sky Harbor International Airport before the holidays in a converted XpresCheck location. Again, we pilot, we learn, we launch. Treat in airport wellness centers will offer services such as COVID-19 testing, travel vaccines, anxiety care, emergency prescriptions, vitamin IV therapies, as well as private technology-lead wellness sessions, including fitness, yoga, meditation, and mindfulness sessions, in a premium hospitality environment. Upon entering, customers will see a beautifully curated retail and check-in area and will be greeted by Treat Wellness coffee areas. Well-appointed treatment rooms will allow a break from the hectic airport environment and offer a list of health and wellness services designed specifically for travelers. We intend to rollout Treat Wellness centers across many additional airports in 2022, and 2023, leveraging our existing XpresSpa real estate. Most importantly, we're building the one travel brand that provides access to integrated holistic care, and can seamlessly fit into a health and wellness lifestyle. Over the long term, we envision that Treat's digital channels will provide more significant growth opportunities for revenue and profit, than our airport real estate. This is because we believe this customer is everywhere and not just captive in the airports. The success of this revenue stream will be achieved through both subscription-based services that provide care and digital tools supporting travel, health, and wellness. Furthermore, we anticipate offering up-stream content that can be monetized for affiliate revenue, as well as curated retail through e-commerce channels. In 2021, we are building the long-term infrastructure and habits to transition from an airport wellness operator to a technology-led Company with unparalleled customer data coming in through multiple channels. And that also operates profitable and convenient health and wellness operations for travelers in airports. While we are excited about this new brand and see Treat as the central pillar to the future of XpresSpa Group, we also now believe that there is a significant opportunity for 3 sustainable growth brands. while healthy unit-level economics can run adjacent to each other and leverage the efficient corporate structure, as well as our relationships and experience operating in global airports. We have an ex -- we have an extremely clear vision for the Company with a focus on elevating our brands, being nimble, further expanding our services and products inside and outside the airports to increase value for all XpresSpa shareholders. As I have expressed here today, we have also assembled an extremely strong management team over the last 6-9 months, which is already contributing today, as seen by our Q1 and Q2 results in recent announcements while laying the foundation for the long-term success of this developing global multichannel Company. We believe that our portfolio of health and loan as brands will enable us to build and enhance shareholder value for years to come. The best days are ahead of us. With that, I'll turn it to you, James.